DrugBiological
Pegunigalsidase alfa clinical trials
Also written PRX-102.
Keep track of what changes. Save the pegunigalsidase alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Protalix (6) · Chiesi Farmaceutici S.p.A. (4)
Studies
Open first, then newest update. How each study uses pegunigalsidase alfa is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseRecruitingPhase 2/3Chiesi Farmaceutici S.p.A.NCT06328608Written as PRX-102 1 mg/kg every two weeks
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseaseRecruitingPhase 2/3Chiesi Farmaceutici S.p.A.NCT05710692Written as PRX-102 1 mg/kg every 2 weeks
- Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease PatientsCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT03614234Written as pegunigalsidase alfa
- Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry DiseaseCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT03566017Written as pegunigalsidase alfa
- Extension Study of PRX-102 for up to 60 MonthsCompletedPhase 1/2ProtalixNCT01981720Written as PRX-102 (pegunigalsidase alfa)
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal FunctionCompletedPhase 3ProtalixNCT02795676Written as PRX-102 (pegunigalsidase alfa)
- Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)CompletedPhase 3ProtalixNCT03018730Written as PRX-102 (pegunigalsidase alfa)
- Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 WeeksCompletedPhase 3ProtalixNCT03180840Written as Pegunigalsidase alfa
- Dose-ranging Study of PRX-102 in Adult Fabry Disease PatientsCompletedPhase 1/2ProtalixNCT01678898Written as PRX-102
- Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry DiseaseWithdrawnPhase 3ProtalixNCT02921620Written as PRX-102
Codes
What other systems call pegunigalsidase alfa · ClinicalTrials.gg INT002167
- MeSH (NLM) C000731937pegunigalsidase alfaOne source NLM
- UNII (FDA) 8M7V7Q6537PEGUNIGALSIDASE ALFAConfirmed FDA, NLM
- NCI Thesaurus C175187Pegunigalsidase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731937 | pegunigalsidase alfa | One source NLM |
| UNII (FDA) | 8M7V7Q6537 | PEGUNIGALSIDASE ALFA | Confirmed FDA, NLM |
| NCI Thesaurus | C175187 | Pegunigalsidase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.